QLS1410

QLS1410 is a **small molecule chemical drug** under development as a selective inhibitor of cytochrome P450 11B2 (CYP11B2), also known as **aldosterone synthase**. Its primary investigational indication is **essential hypertension**. The drug is designed to reduce aldosterone synthesis, and thereby lower blood pressure in individuals with hypertension. Early-stage clinical trials focus on evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of food in healthy adults and adults with mild essential hypertension. QLS1410 is developed by Qilu Pharmaceutical. The highest phase in development is Phase 1, with ongoing studies in China[1][3][5].